eplontersen ATTR Wainua
Selected indexed studies
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (JAMA, 2023) [PMID:37768671]
- Eplontersen: First Approval. (Drugs, 2024) [PMID:38413492]
- Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. (J Clin Med, 2025) [PMID:40649158]
_Worker-drafted node — pending editorial review._
Connections
eplontersen ATTR Wainua is a side effect of
Sources
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (2023) pubmed
- Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. (2024) pubmed
- Eplontersen: First Approval. (2024) pubmed
- Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. (2025) pubmed
- Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. (2024) pubmed
- Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. (2025) pubmed
- Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. (2025) pubmed
- New therapies to treat cardiac amyloidosis. (2025) pubmed
- RNA-targeting and gene editing therapies for transthyretin amyloidosis. (2022) pubmed
- Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review. (2024) pubmed